Pricing Log in Create free account
Saturday 17 October 2026 Export BMY’s income statement to Excel — free account

Bristol Myers Squibb Company

BMY Healthcare Drug Manufacturers General

Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue grew 5.74%, EPS grew 153.1%, free cash flow fell 13.2% and total debt fell 12.3%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.

59.71 0.86 −1.42%
Market cap
$123.7B
P/E
13.2×
Fwd P/E
11.2×
Dividend yield
4.22%
F-score
8/9
Altman Z
2.14
Beneish M
−2.69
Dividend safety
63/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Bristol Myers Squibb Company (BMY) EV/EBITDA

Alert me on EV/EBITDA

As of 16 October 2026, Bristol Myers Squibb Company (BMY) trades at a EV/EBITDA of 10.2×. Over the past ten years it has ranged from 7.0× (February 2024) to 137× (March 2025); the current reading is higher than 22% of that period. That is below the Drug Manufacturers General industry median of 13.8× and above the Healthcare sector median of 9.2×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 10.8× (91.40%)
FY2024 126× 1,573.66%
FY2023 7.5× (26.59%)
FY2022 10.2× 15.68%
FY2021 8.8× (82.26%)
FY2020 49.8× 137.96%
FY2019 20.9× 65.75%
FY2018 12.6× (26.65%)
FY2017 17.2× 8.83%
FY2016 15.8× (66.83%)

Quarterly newest first

Period EV/EBITDA Change
Jun 2026 9.9× (16.94%)
Mar 2026 11.9× 10.55%
Dec 2025 10.8× 12.55%
Sep 2025 9.6× (3.17%)
42 more quarters

Against its own ten years

Low 7.0× High 137×
Ten-year median 15.1×
Current reading's percentile 22

EV/EBITDA against peers

Company EV/EBITDA
NVO Novo Nordisk A/S compare 7.0×
GSK GSK PLC Sponsored ADR compare 9.3×
BMY Bristol Myers Squibb Company 10.2×
PFE Pfizer Inc. compare 10.8×
SNY Sanofi compare 11.1×
AZN AstraZeneca PLC compare 13.8×
NVS Novartis AG compare 14.5×
AMGN Amgen Inc. compare 16.8×
GILD Gilead Sciences, Inc. compare 829×
Drug Manufacturers General industry median 13.8×
Healthcare sector median 9.2×
Market median 11.0×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on BMY